The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion

Sadat, Kamel; Ather, Sameer; AlJaroudi, Wael; Heo, Jaekyeong; Iskandrian, Ami E.; Hage, Fadi G.

doi:10.1007/s12350-013-9846-4

Cited by 20 publications

(17 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three reviews also included participants with AMI or acute coronary syndrome (ACS). 11,13, 14 The number of trials included in the systematic reviews ranged from 5 to 50. All systematic reviews included RCTs, and 3 11,14,15 also included RCTs and cohort studies.…”

Section: Search Strategy and Study Selectionmentioning

confidence: 99%

“…13 Three systematic reviews included trials for both CIHD and AMI or ACS and pooled data from these studies for their primary meta-analysis. 11,13, 14 In subsequent subgroup analysis, 2 reviews suggested that cell therapy significantly improved LVEF in AMI patients but not in CIHD patients. 13, 14 This may be related to the number of included trials for each clinical setting; there were only 4 CIHD studies compared with 14 for AMI in one of the reviews.…”

Section: Primary Outcomesmentioning

confidence: 99%

“…11,13, 14 In subsequent subgroup analysis, 2 reviews suggested that cell therapy significantly improved LVEF in AMI patients but not in CIHD patients. 13, 14 This may be related to the number of included trials for each clinical setting; there were only 4 CIHD studies compared with 14 for AMI in one of the reviews. 13 Although the mean difference in change from baseline LVEF was similar between the AMI and CIHD groups (3.29% and 3.47%, respectively), the 95% CIs were wider for CIHD (2.40-4.55 for AMI, −2.39-8.97 for CIHD).…”

Section: Primary Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

Fisher

Dorée

Taggart

et al. 2015

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp diomyocytes or activating endogenous progenitor cells (for review see Behfar et al 8 ). There is enough clinical evidence to conclude that cell therapies are safe. 9-11 However, not all clinical trials show clinical efficacy. Interestingly, cell-based therapy trials are small 9-11 and therefore conclusions drawn from them have limited statistical power. Systematic reviews and meta-analyses are accepted to be robust and unbiased methods for critical evaluation of clinical evidence and to synthesize results from several clinical trials, thus improving statistical power.Evidence-based medicine (EBM) aims at bringing closer together clinical research and clinical practice in order to make the best decisions about treating individuals or groups of patients. Randomized controlled trials (RCTs) are one of the more robust tools that EBM uses in modern medicine. It is therefore important that new interventions are evaluated through RCTs whenever possible. RCTs and nonRCTs of cell therapies for heart disease have been appraised recently in a number of systematic reviews and meta-analyses. 9-11 However, the clinical evidence in this field is widely dispersed and has not been collated. There is a need to assess overall outcomes, including benefits and harms related to cell therapies for heart disease. To date, no assessment of the quality of these systematic reviews eart failure (HF), secondary to ischemic and nonischemic cardiomyopathy, remains a major cause of death worldwide. As the long term survival of patients suffering from ischemic and nonischemic cardiomyopathy has increased with recent medical advances, the incidence of HF has also steadily increased. The overall mortality for HF stands at 50% within 4 years of diagnosis, and 50% of patients with severe HF die in the first year. 1 Currently, patients suffering from endstage HF require heart transplantation 2 or are supported by left ventricular assist devices (LVAD). 3 However, both the number of organs for transplantation and the longterm efficacy of LVAD are limited. Additionally, artificial pacemakers or implantable cardioverter-defibrillators are indicated for some patients because they help to improve HF symptoms in the short term. Therefore, there is a need for alternative strategies to mitigate symptoms and decelerate the progression to endstage HF.Recently, cell therapies have been investigated as a new treatment for patients suffering from acute myocardial infarction (AMI), 4 chronic ischemic 5 and nonischemic 6 cardiomyopathy and HF. 7 Cell-based therapies have the potential to compensate for the limited ability of the adult heart to repair itself following a major injury by improving vascularity, supporting car- Current Evidence of the Efficacy of Cell-Based Therapies in Heart FailureEmma Harvey, PhD; Sheila A. Fisher, PhD; Carolyn Doree, PhD; David P. Taggart, MD; Enca Martin-Rendon, PhDHeart failure (HF) is the major cause of mortality worldwide. For mor...

show abstract

Section: Search Strategy and Study Selectionmentioning

confidence: 99%

Section: Primary Outcomesmentioning

confidence: 99%

Section: Primary Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

Fisher

Dorée

Taggart

et al. 2015

Circ J

View full text Add to dashboard Cite

show abstract

“…Stem cells can be introduced into tissues or organs to replace diseased or damaged cells with minimal risk of rejection and side effects, and can therefore be applied for disorders of the bone/cartilage, lung, liver and diabetic diseases [1][2][3]. A large number of stem cells should be prepared to achieve satisfactory therapy.…”

Section: Introductionmentioning

confidence: 99%

Approaches for Stimulating Proliferation of Stem Cells in Vitro

Liu¹,

Li²,

Cai³

2017

JAMB

View full text Add to dashboard Cite

Abstract.With the increasing incidence rates in the complex human diseases, e.g., Alzheimer's disease, spinal cord injury, and diabetes, there exists an urgent need to search for more effective and efficient therapies. Cell-based therapy has been considered to be a novel and effective therapeutic approach for the great potential of stem cells in their self-renewal and multipotential differentiational capacity. However, a major difficulty with the success of stem cell therapy is the availability of stem cells. The most serious issue is that only a limited number of stem cells can be extracted from adult tissue due to the decreasing frequency and differentiation potential with age. In order to achieve successful cell-based therapy, extensive ex vivo proliferation of stem cells is urgently required. Therefore, approaches to stimulate proliferation of stem cells are discussed in this article.

show abstract

“…Cellbased therapy is a novel and potential therapeutic approach, which can replace diseased or damaged cells with minimal side effects by introducing stem cells to these tissues or organs [1][2][3][4] . Currently, BMSCs have represented the golden type of stem cell for cell-based therapies.…”

Section: Introductionmentioning

confidence: 99%

Unique Features and Clinical Application Prospect of Human Umbilical Cord Mesenchymal Stem Cells

Dilxat¹,

Li²,

Liu³

2016

International Journal of Orthopaedics

View full text Add to dashboard Cite

MSCs. Moreover, MSCs harvested from hUC are pluripotent and immunologically naive. The morphology and biological characteristic of hUC-MSCs resembles that of MSCs isolated from bone marrow. CONCLUSION: Cell-based therapy is an emerging field, which can offer great therapeutic potential in the complex human diseases. Compared with bone marrow, hUC has been considered as an ideal source of MSCs due to their little ethical obstacles, painless procedures involved, lower risk of immune rejection and convenient sources for autologous cell therapy. The rapid development of umbilical cord blood banks appears to provide plentiful supply of stem cells for regenerative medicine and tissue engineering. INTRODUCTIONWith the increasing prevalence and incidence rates in the complex human diseases, e.g., bone regeneration disease, cardiovascular disease, diabetic disease and hematopoietic disease, there exits an urgent need to search for more effective and efficient therapies. Cellbased therapy is a novel and potential therapeutic approach, which can replace diseased or damaged cells with minimal side effects by introducing stem cells to these tissues or organs [1][2][3][4] . Currently, BMSCs have represented the golden type of stem cell for cell-based therapies. Experimental and clinical studies have showed the selfrenewal and multilineage differentiation capability of BMSCs [5][6][7] . However, it is quite difficult to produce large quantities of tissue/cells via bone marrow due to the decreasing frequency and differentiation potential with age. The harvesting of BMSCs also involves invasive procedures [8] . Therefore, the search for substitute of BMSCs is of ABSTRACT AIM: The purpose of the study was to summarize the unique features of human umbilical cord mesenchymal stem cells (hUC-MSCs) and their clinical application prospect.

show abstract

The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion

Abstract: BMC transfer appears to have a positive impact on LV recovery in patients with acute coronary syndrome and those with stable coronary disease with or without heart failure. Most studies were small and a minority used a core laboratory for image analysis.

Cited by 20 publications

References 72 publications

Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

Approaches for Stimulating Proliferation of Stem Cells in Vitro

Unique Features and Clinical Application Prospect of Human Umbilical Cord Mesenchymal Stem Cells

Contact Info

Product

Resources

About